Collegium Pharmaceutical, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $21.30 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2021-02-25
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $16.01, a 33.92% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $24.23, a 59.41% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $15.20, a 6.06% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $16.18.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $21.30, a 39.95% increase from fiscal 2019.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $15.22.
- Collegium Pharmaceutical, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $23.76.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $21.30 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | $15.22 10-K · filed 2020-02-27 | ||||
| 2019-09-30 | $15.08 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $15.67 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $16.01 10-Q · filed 2019-05-08 | ||||
| 2018-09-30 | $23.89 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $24.17 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $24.23 10-Q · filed 2018-05-09 | ||||
| 2017-12-31 | $23.76 10-K · filed 2019-02-27 | $12.30 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $12.06 10-Q · filed 2017-11-08 | ||||
| 2017-06-30 | $12.11 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | $15.20 10-Q · filed 2017-05-10 | ||||
| 2016-09-30 | $16.50 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $16.60 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $16.18 10-Q · filed 2016-05-11 | ||||
| 2015-09-30 | $10.47 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |